Health
GLP-1 Medications: New Frontiers in Chronic Disease
Health Points
- GLP-1 medications are transforming treatment for diabetes, obesity, and may help other chronic illnesses.
- These drugs work on multiple body systems and are being studied for heart disease, sleep apnea, and kidney disease.
- Recent FDA approvals highlight their expanding potential to address major health risks in adults.
GLP-1 drugs, such as Ozempic and Wegovy, have changed how we approach type 2 diabetes and obesity, making a significant impact on adult health. Now, researchers are testing over 1,700 clinical trials to see if these medications can also support conditions like heart disease, stroke, Alzheimer’s, PCOS, and even certain cancers.
Experts believe GLP-1s show promise because they address insulin resistance and inflammation, which affect many organ systems. “There is no organ system that is not affected by this internal metabolic environment,” says Dr. Jamy Ard, epidemiology specialist.
GLP-1s help curb calorie intake and may influence glucose metabolism and lower inflammation, but it’s not clear if these effects come directly from the medication or from weight loss.
“These receptors in other areas of the body make it promising to use GLP-1s to treat other conditions,” says Diana Isaacs, PharmD, about the widespread presence of GLP-1 receptors in organs like the heart, brain, and kidneys.
Wegovy became the first GLP-1 medication approved to treat heart disease in people with excess weight, after studies showed a significant drop in heart attacks and strokes. Interestingly, the SELECT trial noted only moderate weight loss, suggesting other beneficial effects may be at work.
Clinical trials for a semaglutide pill continue, showing potential for reducing cardiovascular events in people with diabetes and heart disease.
The FDA also recently approved Zepbound for obstructive sleep apnea in adults with obesity, acknowledging clinical trial results that showed reduced symptoms alongside weight loss.
According to the FLOW trial, semaglutide may slow the progression of chronic kidney disease and reduce the risk of death related to the heart and kidneys, leading to its newest FDA approval for these conditions.
GLP-1s are quickly expanding beyond diabetes care, offering fresh hope for several long-term health issues impacting adults over 40. Talk with your healthcare provider about what’s ahead for these innovative medications and if they might be right for your health journey.
